Pfizer and Novo Nordisk risk overpaying in their high-profile and unusual bidding war for Metsera, the anti-obesity drug company that doesn't have any approved products and already faces GLP-1 pricing pressure.
The big picture: Whatever the outcome of its complex choice, Metsera is almost guaranteed to sell for much more than its $7.3 billion valuation of just a couple months ago.
